Page 35 - HP2017FIN4PRN.indd

Micro Labs Hikma Pharmaceuticals

Micro Labs Limited is a multi-faceted healthcare organization with a Hikma Pharmaceuticals PLC is a fast growing multinational
proficient marketing team, state-of-the-art manufacturing facilities pharmaceutical group which was founded in 1978 in Jordan. Hikma
and R&D centres that are at par with international standards. All this, develops, manufactures and markets a broad range of both branded
robustly backed by a strong distribution network and path-breaking and non-branded generic and in-licensed products. Hikma is
research work has placed us amongst India’s fast growing committed to the highest quality manufacturing with multiple FDA
transnational healthcare organizations. approved facilities. Hikma operates in the US, Europe and across the
MENA region. Growth in MENA is driven by strong demographics
Ranking 10th among prescriptions and 20th in sales, Micro’s brand and growing investment in healthcare. Hikma delivered 23% revenue
portfolio includes some of the topmost brands in various specialties growth, underlying its strong financial record in 2013. Hikma is the
like Cardiology, Diabetology, Anti-infectives, Ophthalmology, Pain, fourth listed pharmaceutical company in the FTSE 250. As of Dec.
etc. Amidst our proud achievers is Dolo, an award-winning brand 2013 Hikma’s global team was made up of 7,067 employees.
highly prescribed for fever management.
Operations are in 27 manufacturing facilities in 11 countries - FDA
The company is also at the forefront in social contribution, striving to approved facilities in 5 countries with cost effective R&D and
be a model corporate citizen in terms of Environmental Protection & manufacturing.
Social Initiatives with significant contributions in the areas of
education and health. Our strategy for growth is to strengthen our leading
position in the MENA region, develop our global product
Micro Labs is poised to achieve unparalleled status in the global range in growing therapeutic areas, extend our reach and
pharmaceutical industry. Backed by a profound and resolute vision, diversity as partner of choice in the MENA region,
we now have our eyes set on attaining the $1 billion mark by 2015. increase the scale of our specialty injectables business,
leverage our expertise and
capacity in the US
market, build on our
world-class
manufacturing and API
sourcing capabilities.